NIU Technologies reported its Q2 2024 financial results, achieving over $100 million in revenue, indicating strong growth. In the healthcare sector, several companies disclosed their quarterly results. Y-mAbs Pharmaceuticals, listed as $YMAB, announced a GAAP EPS of $(0.21), missing the expected $(0.15), with sales of $22.8 million, also below the $23 million estimate. The company anticipates total net revenues for FY 2024 to be between $87 million and $95 million, slightly below the consensus of $95.1 million. Neuronetics, which recently announced a merger with Greenbrook TMS, projected $145 million in revenue for 2023 and expects $15 million in cost savings along with mid-teens growth for 2025-2026. Esperion Therapeutics reported mixed Q2 results while reaffirming its FY 2024 outlook. Apogee Therapeutics provided updates on its pipeline alongside its Q2 financial results. Other companies such as Adaptimmune, Abeona Therapeutics, and Gossamer Bio also released their second-quarter financial results, reflecting a busy earnings season in the biotech sector.